Live Breaking News & Updates on Oph All

Stay updated with breaking news from Oph all. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Disparities in Access to Care for Ph+ ALL patients

The panel discusses disparities in the quality of care received by Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients. ....

Access To Care , Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia , Oph All , Oral Chemotherapy , Tyrosine Kinase Inhibitor , High Cost Therapies , Care Management , Hospital Admission , Insurance Coverage , Medical Benefit ,

Optimizing Real-World Ponatinib Use in Ph+ ALL: Treatment Considerations

Insights on real-world ponatinib treatment strategies and safety in Philadelphia-positive acute lymphoblastic leukemia are provided by Hagop Kantarjian, MD, and Bijal D. Shah, MD, MS. ....

Hagopm Kantarjian , Bijald Shah , Acute Lymphoblastic Leukemia , Call Cancer , Oph All , Ph Acute Lymphoblastic Leukemia , Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia , Newly Diagnosed All , Newly Diagnosed Acute Lymphoblastic Leukemia , Ponatinib Based Therapy , Ponatinib Safety , Ponatinib Efficacy , Ponatinib Dose Adjustment , Blinatumomab Combination , Molecular Response , Cns Relapse , Allogeneic Stem Cell Transplantation , Fda Approval Of Ponatinib , Ponatinib Approval , Ikaros Positive , Combination Therapy , Novel Therapy ,

Ponatinib Advances as Frontline Therapy in Ph+ ALL: PhALLCON Study Highlights

Bijal Shah, MD, MS, and Hagop Kantarjian, MD, discuss promising results and regulatory progress for ponatinib in frontline Philadelphia-positive acute lymphoblastic leukemia treatment. ....

Bijal Shah , Hagop Kantarjian , Expert Insights , Newly Diagnosed , Frontline Therapy , Acute Lymphoblastic Leukemia , Call Cancer , Oph All , Ph Acute Lymphoblastic Leukemia , Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia , Newly Diagnosed All , Newly Diagnosed Acute Lymphoblastic Leukemia , Tki Therapy , Comparative Trials , Hypercvad Therapy , Broad Acting Tki , Compound Mutations , Phallcon Study , Phallcon Trial , Low Intensity Chemotherapy , Imatinib Therapy , Ponatinib Therapy , Dasatinib Therapy , Novel Therapy , Combination Therapy ,

Advancing the Treatment Landscape in Philadelphia-Positive ALL

Key opinion leaders review the evolution of Ph+ ALL treatment, from Hyper-CVAD to novel TKIs, blinatumomab, and deintensification, improving remission rates and survival. ....

United States , Expert Insights , Newly Diagnosed , Treatment Landscape , Acute Lymphoblastic Leukemia , Call Cancer , Oph All , Ph Acute Lymphoblastic Leukemia , Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia , Newly Diagnosed All , Newly Diagnosed Acute Lymphoblastic Leukemia , Abl Rearranged Leukemia , Hypercvad Therapy , Next Generation Sequencing , Fish Testing , Bcr Abl Translocation , Unmet Needs In All , Tki Combinations For All , Dasatinib Therapy , Allogeneic Stem Cell Transplantation , Alliance Data , Alliance Trial , Third Generation Tkis , Ponatinib Therapy , Blinatumomab Therapy , Treatment Deintensification ,

First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Ph+ ALL

Expert Elias Jabbour, MD, reviews clinical data from the PhALLCON study of ponatinib vs imatinib in patients with Ph+ acute lymphocytic leukemia and considers its clinical implications. ....

Elias Jabbour , First Report , Comparing Ponatinib , Newly Diagnosed , Acute Lymphocytic Leukemia , Call Cancer , All Leukemia , Ph Positive , Oph All , Tyrosine Kinase Inhibitors , Tki Therapy , Combination Therapy , Bcr Abl , Ponatinib Dose , Ponatinib Dosing , Complete Response , Survival Data , Adverse Events , Drug Adverse Event , Mrd Negativity , Mrd Negative , Duration Of Response , Crossover Therapy , Sequencing Therapy , Event Free Survival , Efs Data ,